A drug called OBI-3424 has been designated an Orphan Drug by the U.S. Food and Drug Administration (FDA) to treat acute lymphoblastic leukaemia, based predominantly on research carried out by our Leukaemia Biology Program.
This week we’re looking at immunotherapy. Harnessing the power of the immune system against cancer is yielding some amazing results. So what are the promises and challenges of immunotherapy?
This week we’re exploring cancer genomics. What is it, why is it important, and how can we use it to improve cancer treatment?
September is International Childhood Cancer Awareness month. In a series of weekly blog posts throughout September, you’ll see how we’re using our strategy of ‘Discover and Translate’ to improve outcomes for kids with cancer.
Research published this week shows that gold-coated nanoparticles can be used to detect tiny amounts of cancer-related molecules in blood.
Last week we hosted a delegation of eight doctors from two leading Chinese children’s hospitals, opening up exciting possibilities for research and clinical collaborations
A database of genetic information of more than 270 cancer models, encompassing 25 different childhood cancers, has just been made publicly available. Children’s Cancer Institute contributed 90 leukaemia models to this global effort.
The 9th International Nanomedicine Conference was held last week in Coogee, Sydney. Some of our researchers were there, showcasing their research and networking with colleagues from near and far.
We’ve just launched our Strategic Plan for 2018–2022. The culmination of months of consultation and thought, it provides a road map for achieving our vision as quickly as possible.
How does the future look for young Australians with cancer? According to a recent article by Cancer Institute NSW, it’s looking brighter, and our work’s playing a vital role.